DCTH 9.63 (-2.83%)
US24661P8077Medical Devices & InstrumentsMedical Devices

Delcath Systems (DCTH) Stock Highlights

9.63 | -2.83%
2024-11-21 05:04:50
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firms product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Statistics

Range Today
9.5 10.04
Volume Today 391.9K
Range 1 Year
2.47 12.88
Volume 1 Year 74.01M
Range 3 Year
2.25 12.88
Volume 3 Year 245.44M
Range 10 Year
2.25 7210
Volume 10 Year 284.69M

Highlights

Market Capitalization 309.69M (small)
Floating Shares 20.51M
Current Price 9.63
Price To Earnings -4.74
Price To Revenue 25.91
Price To Book 15.96
Earnings Per Share -2.52
Payout Ratio 0%

Performance

Latest -2.83%
1 Month -15.67%
3 Months +20.38%
6 Months +28.92%
1 Year +283.67%
3 Years -5.5%
5 Years -67.24%
10 Years -99.22%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.